Literature DB >> 2521515

Effects of buspirone and its metabolite, 1-(2-pyrimidinyl)piperazine, on brain monoamines and their metabolites in rats.

R W Fuller1, K W Perry.   

Abstract

Buspirone, an anxiolytic drug with selective affinity for the 5-HT-1A subtype of serotonin receptors, caused a dose-related decrease in 5-hydroxyindole acetic acid (5-HIAA) concentration in rat hypothalamus after doses of 1 to 10 mg/kg s.c. The decrease in 5-HIAA concentration after a 3 mg/kg s.c. dose of buspirone persisted at 4 hr but not at 7 hr. The decrease was due apparently to a reduced turnover of serotonin; the accumulation of 5-hydroxytryptophan after decarboxylase inhibition was also suppressed by buspirone, not only in hypothalamus but also in brain stem, hippocampus and striatum. 1-(2-Pyrimidinyl)-piperazine (1-PP), a major metabolite of buspirone, did not affect hypothalamic 5-HIAA concentration at doses up to 10 mg/kg s.c. Both buspirone and 1-PP increased hypothalamic concentrations of 3-methoxy-4-hydroxyphenylethyleneglycol (MHPG) sulfate, the norepinephrine metabolite, the effect being more pronounced with 1-PP but occurring after doses as low as 0.3 mg/kg s.c. with each compound. The increase in MHPG sulfate concentration persisted for at least 4 hr after a 3 mg/kg s.c. dose of each compound. The increase in MHPG sulfate produced by buspirone may have been due partly to 5-HT-1A receptor activation, inasmuch as other serotonin agonists have been found to cause a similar increase. 1-PP is reported to lack affinity for 5-HT-1A receptors so its elevation of MHPG sulfate concentration may have resulted from alpha-2 receptor blockade. The increase in MHPG sulfate concentration after buspirone injection may have been due at least partly to formation of the metabolite, 1-PP.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2521515

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  15 in total

1.  Neurochemical evidence for antagonism by olanzapine of dopamine, serotonin, alpha 1-adrenergic and muscarinic receptors in vivo in rats.

Authors:  F P Bymaster; S K Hemrick-Luecke; K W Perry; R W Fuller
Journal:  Psychopharmacology (Berl)       Date:  1996-03       Impact factor: 4.530

2.  Pharmacological profile of a potential anxiolytic: AP159, a new benzothieno-pyridine derivative.

Authors:  T Nagatani; T Yamamoto; K Takao; S Hashimoto; K Kasahara; T Sugihara; S Ueki
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

3.  The effects of buspirone on occupancy of dopamine receptors and the rat gambling task.

Authors:  Patricia Di Ciano; Patrick Mc Cormick; Cristiana Stefan; Ernest Wong; Aaron Kim; Gary Remington; Bernard Le Foll
Journal:  Psychopharmacology (Berl)       Date:  2017-08-19       Impact factor: 4.530

4.  Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease.

Authors:  Y Du; Z Ma; S Lin; R C Dodel; F Gao; K R Bales; L C Triarhou; E Chernet; K W Perry; D L Nelson; S Luecke; L A Phebus; F P Bymaster; S M Paul
Journal:  Proc Natl Acad Sci U S A       Date:  2001-11-27       Impact factor: 11.205

5.  Increased levels of extracellular noradrenaline in the frontal cortex of rats exposed to naturalistic environmental stimuli: modulation by acute systemic administration of diazepam or buspirone.

Authors:  J W Dalley; K Mason; S C Stanford
Journal:  Psychopharmacology (Berl)       Date:  1996-09       Impact factor: 4.530

6.  Mechanism-based pharmacokinetic/pharmacodynamic modeling of rat prefrontal cortical dopamine response to dual acting norepinephrine reuptake inhibitor and 5-HT1A partial agonist.

Authors:  Cheryl Shuang-wu Li; Liming Zhang; Taraneh Haske; Amy Dounay; David Gray; Nancy Barta; Joanne Brodfuehrer; Christopher Lepsy; Brian Campbell
Journal:  AAPS J       Date:  2012-03-28       Impact factor: 4.009

7.  Fluoxetine increases norepinephrine release in rat hypothalamus as measured by tissue levels of MHPG-SO4 and microdialysis in conscious rats.

Authors:  K W Perry; R W Fuller
Journal:  J Neural Transm (Vienna)       Date:  1997       Impact factor: 3.575

8.  Effect of the 5-HT1A partial agonist buspirone on regional cerebral blood flow in man.

Authors:  P M Grasby; K J Friston; C Bench; P J Cowen; C D Frith; P F Liddle; R S Frackowiak; R J Dolan
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

9.  The orexin-1 antagonist SB-334867 blocks antipsychotic treatment emergent catalepsy: implications for the treatment of extrapyramidal symptoms.

Authors:  Kurt Rasmussen; Mei-Ann Hsu; Stephen Noone; Bryan G Johnson; Linda K Thompson; Susan K Hemrick-Luecke
Journal:  Schizophr Bull       Date:  2007-07-28       Impact factor: 9.306

10.  Fluoxetine at anorectic doses does not have properties of a dopamine uptake inhibitor.

Authors:  R W Fuller; S K Hemrick-Luecke; H D Snoddy
Journal:  J Neural Transm Gen Sect       Date:  1994
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.